A Phase 2 interventional study of budesonide and placebo in Asthma, sponsored by AstraZeneca. Completed at 87 sites in 7 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2014-08-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 36th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2010, is one of 5 in phase 2, and was the 66th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 101st largest by enrollment of the 248 interventional ones that give a count, is one of 15 that started in 2010, is one of 50 in phase 2, and was the 139th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to \<12 years
Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 �g bid with placebo: a 6-week efficacy and safety study in children aged 6 to \<12 years with asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
Drug: budesonide
Placebo pMDI 2 inhalations bid
Drug: placebo
pMDI, inhalation, bid, 6 weeks
pMDI, inhalation, bid, 6 weeks
Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average
The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
Time frame: Baseline to 6 weeks
Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average
FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
Time frame: Baseline to 6 weeks
Change in Evening PEF From Baseline to the Treatment Period Average
The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
Time frame: Baseline to 6 weeks
Change in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average
FVC is the total volume of air expired after a full inspiration. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
Time frame: Baseline to 6 weeks
Change in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average
FEF25-75 is the average rate of airflow during the midportion of the forced vital capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
Time frame: Baseline to 6 weeks
Change in Total Daily and Daytime Asthma Symptom Scores From Baseline to Treatment Period Average
Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.
Time frame: Baseline to 6 weeks
Change in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average
Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.
Time frame: Baseline to 6 weeks
Change in Nighttime Awakenings and Nighttime Awakenings With Reliever Medication Use From Baseline to Treatment Period Average
Patients, with the help of their caregiver, were asked to respond to a standard question each morning as they completed their eDiary. The question to be answered was, "Did your asthma cause you to wake-up last night?" If yes, patients were asked, "Did you need to use your reliever medication (albuterol/salbutamol inhaler) before you went back to sleep?" Baseline is defined as the percentage of days where patient experienced nighttime awakenings out of all available days where data was collected during the last 7 days of the run-in period.
Time frame: Baseline to 6 weeks
Change in Total Daily and Daytime Reliever Medication Use From Baseline to Treatment Period Average
The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"
Time frame: Baseline to 6 weeks
Change in Nighttime Reliever Medication Use From Baseline to Treatment Period Average
The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"
Time frame: Baseline to 6 weeks
Number of Withdrawals Due to Pre-defined Asthma Events
Patients were considered to have experienced a "pre-defined asthma event" if any of the following conditions were met during the study: 1. At each visit or follow-up visit, a decrease in morning pre-dose FEV1 \>=20% from the Visit 3 (randomization visit) morning pre-dose FEV1 or a decrease to \<65% of predicted normal value; 2. The use of \>=8 actuations of albuterol/salbutamol per day on 3 or more days within any period of 7 consecutive days following randomization; 3. A decrease in morning PEF \>=20% from baseline on 3 or more days within any period of 7 consecutive days after randomization; 4. Two or more nights with an awakening due to asthma, which required the use of reliever medication within any period of 7 consecutive days after randomization; 5. A clinical exacerbation requiring emergency treatment, hospitalization, or use of an asthma medication not allowed by the study protocol.
Time frame: Baseline to 6 weeks
This multicenter study was conducted in Bulgaria, Hungary, Latvia, Poland, Slovakia, South Africa, and the United States between 07 August 2011 and 05 April 2013.
| Milestone | Placebo | Budesonide |
|---|---|---|
| Started | 152 | 152 |
| Completed | 92 | 121 |
| Not completed | 60 | 31 |
| Withdrew: Other | 8 | 3 |
| Withdrew: Study-specific withdrawal criteria | 48 | 25 |
| Withdrew: Severe non-compliance to protocol | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 |
The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
| liters/minute | Placebo | Budesonide |
|---|---|---|
| Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average | 4.1 ± 3.19 | 17.8 ± 3.24 |
FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
| liters | Placebo | Budesonide |
|---|---|---|
| Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average | 0.00 ± 0.023 | 0.06 ± 0.023 |
The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
| liters/minute | Placebo | Budesonide |
|---|---|---|
| Change in Evening PEF From Baseline to the Treatment Period Average | 4.0 ± 3.08 | 14.7 ± 3.13 |
FVC is the total volume of air expired after a full inspiration. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
| liters | Placebo | Budesonide |
|---|---|---|
| Change in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average | 0.00 ± 0.021 | 0.04 ± 0.021 |
FEF25-75 is the average rate of airflow during the midportion of the forced vital capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.
| liters/second | Placebo | Budesonide |
|---|---|---|
| Change in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average | 0.01 ± 0.045 | 0.11 ± 0.045 |
Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.
| units on a scale | Placebo | Budesonide |
|---|---|---|
| Daytime asthma symptom score | -0.2 ± 0.06 | -0.4 ± 0.06 |
| Total asthma symptom score | -0.5 ± 0.11 | -0.8 ± 0.11 |
Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.
| units on a scale | Placebo | Budesonide |
|---|---|---|
| Change in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average | -0.3 ± 0.06 | -0.4 ± 0.06 |
Patients, with the help of their caregiver, were asked to respond to a standard question each morning as they completed their eDiary. The question to be answered was, "Did your asthma cause you to wake-up last night?" If yes, patients were asked, "Did you need to use your reliever medication (albuterol/salbutamol inhaler) before you went back to sleep?" Baseline is defined as the percentage of days where patient experienced nighttime awakenings out of all available days where data was collected during the last 7 days of the run-in period.
| percentage of days with awakenings | Placebo | Budesonide |
|---|---|---|
| Nighttime awakenings | -9.8 ± 1.81 | -14.5 ± 1.84 |
| Nighttime awakenings with reliever use | -6.1 ± 1.17 | -10.0 ± 1.18 |
The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"
| inhalations per day | Placebo | Budesonide |
|---|---|---|
| Daytime reliever medication use | -0.1 ± 0.07 | -0.4 ± 0.07 |
| Total reliever medication use | -0.3 ± 0.11 | -0.7 ± 0.11 |
The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"
| inhalations per day | Placebo | Budesonide |
|---|---|---|
| Change in Nighttime Reliever Medication Use From Baseline to Treatment Period Average | -0.1 ± 0.06 | -0.4 ± 0.06 |
Patients were considered to have experienced a "pre-defined asthma event" if any of the following conditions were met during the study: 1. At each visit or follow-up visit, a decrease in morning pre-dose FEV1 \>=20% from the Visit 3 (randomization visit) morning pre-dose FEV1 or a decrease to \<65% of predicted normal value; 2. The use of \>=8 actuations of albuterol/salbutamol per day on 3 or more days within any period of 7 consecutive days following randomization; 3. A decrease in morning PEF \>=20% from baseline on 3 or more days within any period of 7 consecutive days after randomization; 4. Two or more nights with an awakening due to asthma, which required the use of reliever medication within any period of 7 consecutive days after randomization; 5. A clinical exacerbation requiring emergency treatment, hospitalization, or use of an asthma medication not allowed by the study protocol.
| participants | Placebo | Budesonide |
|---|---|---|
| Number of Withdrawals Due to Pre-defined Asthma Events | 50 | 25 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Budesonide pMDI 160mcg b.i.d. | — | 0/152 (0%) | 27/152 (17.8%) |
| Placebo pMDI b.i.d. | — | 0/152 (0%) | 40/152 (26.3%) |
| Event | Budesonide pMDI 160mcg b.i.d. | Placebo pMDI b.i.d. |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 12/152 | 9/152 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 1/152 | 11/152 |
| PHARYNGITISInfections and infestations | 5/152 | 8/152 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/152 | 8/152 |
| INFLUENZAInfections and infestations | 4/152 | 4/152 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 3/152 | 4/152 |
| Age, Continuous(years) | Placebo | Budesonide | Total |
|---|---|---|---|
| Mean | 9.0 ± 1.62 | 9.0 ± 1.63 | 9.0 ± 1.62 |
| Age, Customized(participants) | Placebo | Budesonide | Total |
|---|---|---|---|
| 6 to <8 years | 33 | 33 | 66 |
| 8 to- <12 years | 119 | 119 | 238 |
| Sex: Female, Male(Participants) | Placebo | Budesonide | Total |
|---|---|---|---|
| Female | 58 | 54 | 112 |
| Male | 94 | 98 | 192 |
| Race/Ethnicity, Customized(participants) | Placebo | Budesonide | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 11 | 21 |
| Native Hawaiian/Pacific Islander | 1 | 0 | 1 |
| African American | 7 | 9 | 16 |
| Asian (other than Chinese and Japanese) | 0 | 2 | 2 |
| Not Applicable | 128 | 126 | 254 |
| Other | 6 | 4 | 10 |
| Forced expiratory volume in 1 second (FEV1)(liters) | Placebo | Budesonide | Total |
|---|---|---|---|
| Mean | 1.70 ± 0.416 | 1.69 ± 0.388 | 1.70 ± 0.401 |
The record gives a start of Jul 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide